H. B. Fuller (FUL) is a Top-Ranked Value Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
H.B. Fuller Company (FUL) Q3 2026 Earnings Call Transcript
H.B. Fuller Company (FUL) Q3 2026 Earnings Call Transcript
H. B. Fuller Q3 Earnings Call Highlights
H. B. Fuller NYSE: FUL reported third-quarter fiscal 2026 revenue growth and higher profitability as pricing actions and restructuring savings more than offset lower volumes and elevated raw-material costs.
H.B Fuller: Undervaluation Getting Clearer
H.B. Fuller (FUL) is rated a 'BUY' with a fair value of $81/share and a price target of $65/share, reflecting significant undervaluation. Despite weak volume trends and elevated leverage post-AMS acquisition, FUL's EBITDA, margins, and EPS are all improving, supporting the investment thesis. At current levels near $51/share, FUL trades at just 8.5x normalized forward EPS, offering market-beating upside even without multiple expansion.
Stay Ahead of the Game With H. B. Fuller (FUL) Q3 Earnings: Wall Street's Insights on Key Metrics
Get a deeper insight into the potential performance of H. B. Fuller (FUL) for the quarter ended August 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Should Value Investors Buy H. B. Fuller (FUL) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
FUL or NVZMY: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Chemical - Specialty sector might want to consider either H. B. Fuller (FUL) or Novozymes A/S (NVZMY).
Here's Why H. B. Fuller (FUL) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
H.B. Fuller Company's Complexity Offers Potential
H.B. Fuller Company remains a Buy candidate, with recent improvements in revenue and profitability despite prior underperformance and share price decline. FUL's acquisition of Advanced Medical Solutions Group expands its total addressable market by $15 billion, but increases leverage and hinges on realizing $55 million in synergies. The company is evaluating an unsolicited $1.1–$1.2 billion cash offer for its Building Adhesives Solutions segment, which could reduce debt but permanently lower profitability.
Are Investors Undervaluing H. B. Fuller (FUL) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
FUL vs. NVZMY: Which Stock Is the Better Value Option?
Investors interested in Chemical - Specialty stocks are likely familiar with H. B. Fuller (FUL) and Novozymes A/S (NVZMY).
Is H. B. Fuller (FUL) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
